Welcome to the NRG Oncology eNewsletter

If you have a suggestion or would like to submit content to our Communications team, please email communications@nrgoncology.org

The NRG Oncology Podcast - New Episodes!

The NRG Oncology Podcast, hosted by Drs. Stephen Chun and Lauren Henke, delves into a variety of topics impacting the oncology community through interviews with NRG Oncology stakeholders.

Listen on Apple, Spotify, Amazon, and YouTube.

Protocol Support Committee (PSC) Column

NRG Oncology PSC 2025 Summer Meeting Wrap Up

Written by: Erin McCaig RN, BSN from Cancer Research for the Ozarks

On behalf of the Protocol Support Committee (PSC), we would like to thank everyone who attended the NRG Oncology Semiannual Meeting in Washington, DC. There were 104 in-person attendees and 169 virtual attendees at the PSC Nurse/CRA Continuing Education Session Thursday morning. There were 340 table visits and 171 virtual attendees at the afternoon Roundtable Discussions. The PSC Protocol Spotlight session on Friday morning included 70 in-person and 148 virtual attendees.

Advocate Angle

A Message of Support from the New PAC Chair, Tambre Leighn

Photo courtesy of Tambre Leighn

NRG Study News & New Protocols Under Development

New Protocols Under Development

Protocol Activation!

NRG-GU015: The Phase III Adaptive Radiation And Chemotherapy For Muscle Invasive Bladder Cancer Trial (ARCHER)

Now open to patient entry, NRG Oncology's new clinical trial, NRG-GU015 “ARCHER,” will study a shorter duration of radiation therapy for patients with muscle invasive bladder cancer.

Dual Immune Checkpoint Inhibition with Radiotherapy does not Improve Progression-Free Survival for Patients with Newly Diagnosed MGMT-unmethylated Glioblastoma

NRG Oncology recently reported the results of the National Cancer Institute sponsored phase II/III NRG-BN007 clinical trial (https://clinicaltrials.gov/study/NCT04396860) showing that combining ipilimumab and nivolumab with radiation therapy (RT) did not improve progression-free survival (PFS) for patients with newly diagnosed MGMT-unmethylated (uMGMT) glioblastoma in comparison to standard RT with temozolomide (TMZ). Accordingly, this trial will not progress to a phase III. These results were recently published in the Journal of Clinical Oncology (https://doi.org/10.1200/JCO-25-00618).

FORTE Study Updates

RECAP: FORTE Coordinator Session - July 29, 2025

The NRG Oncology FORTE team hosted the FORTE Coordinator Session with support from the FORTE Coordinator Committee on July 29, 2025, coinciding with the NRG Summer Meeting.

NRG News

NRG Oncology Appoints New NCORP and Veteran Affairs Research Leadership

Julie Bauman, MD, MPH, was appointed Deputy Chair of NRG’s NCORP Research Base replacing Dr. Lisa Kachnic who was recently named an NRG NCORP Multi-Principal Investigator (MPI).

Ryan Burri, MD, was selected as the VA-MTF Subcommittee Vice Chair replacing Maria Kelly who recently stepped down from the role.

Call for Applications: NRG Health Care Access Fellowship

Applications DUE September 19, 2025

NRG Oncology is currently seeking applications for the NRG Health Care Access Fellowship. This program trains selected early-stage investigators in the NRG Oncology system by means of a structured mentorship experience, with particular emphasis given to the recruitment of researchers with a passion for improving health care access. Our vision is to have at least one scholar for every disease site we study. Awards will be announced in November. Fellowship Start Date: January 1, 2026

RFA for medical oncologist Vice Chair, NRG Oncology Head and Neck Cancer Committee - Applications DUE September 1, 2025

RFA for medical oncologist VICE Chair, NRG Oncology Lung Cancer Committee - Applications DUE September 1, 2025